

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity: CHEMGENEX PHARMACEUTICALS LIMITED
ABN: 79 000 248 304

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Geoff Brooke
Date of last notice	12 June 2009

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Geoff Brooke is Managing Partner of GBS Venture Partners Pty Ltd.  Fully paid ordinary shares (ASX Code: CXS) and listed options (ASX Code: CXSOA) are held by GBS Venture Partners Pty Ltd as trustee for GBS Bioventures III.
Date of change	6 May 2011
No. of securities held prior to change	21,942,255 fully paid ordinary shares (ASX Code: CXS) held indirectly; 2,736,065 listed options (ASX Code: CXSOA) held indirectly; and 250,000 unlisted options exercisable at \$1.22 per option held directly.
Class	Fully paid ordinary shares and listed options
Number acquired	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Number disposed</b>	21,942,255 fully paid ordinary shares (ASX Code: CXS) held indirectly; 2,736,065 listed options (ASX Code: CXSOA) held indirectly.
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$15,359,578.50 (\$0.70 per fully paid ordinary share) \$54,721.30 (\$0.02 per listed option)
<b>No. of securities held after change</b>	250,000 unlisted options exercisable at \$1.22 per option held directly.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acceptance of Share Offer and Listed Option Offer in accordance with terms and conditions of the Share Offer and Listed Option Offer outlined in the Bidder's Statement announced on 13 April 2011.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

---

+ See chapter 19 for defined terms.

**Part 3 – +Closed period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	



Date: 6 May 2011

Print name: James Campbell, Company Secretary

---

+ See chapter 19 for defined terms.